Quelltext der Seite CD27-Antigen

{{Infobox Protein
| Name           = CD27 antigen
| Bild           = 
| Bild_legende   = 
| Andere Namen   = CD27L receptor, T-cell activation antigen CD27, T14, Tumor necrosis factor receptor superfamily member 7
| PDB            = 
| Groesse        = 260 [[Aminosäuren]], 29.137 [[Atomare Masseneinheit|Da]]
| Kofaktor       =
| Precursor      =
| Struktur       =
| Isoformen      =
| HGNCid         = 11922
| Symbol         =
| AltSymbols     =
| GeneCards      = CD27
| OMIM           =
| UniProt        = P26842
| MGIid          =
| CID            =
| CAS            =
| CASergänzend   =
| ATC-Code       =
| DrugBank       =
| Wirkstoffklasse =
| TCDB           =
| TranspText     =
| EC-Nummer      = 
| Kategorie      =
| Peptidase_fam  =
| Inhibitor_fam  =
| Reaktionsart   =
| Substrat       =
| Produkte       =
| MoreEC1        =
| MoreEC2        =
| MoreEC3        =
| Homolog_db     = HBG018200
| Homolog_fam    =
| Taxon          =
| Taxon_Ausnahme =
| Orthologe      =
}}

'''CD27 antigen''' ist ein [[Oberflächenprotein]] aus der Gruppe der [[TNF-Rezeptor]]en.

== Eigenschaften ==
CD27 ist der [[Rezeptor (Biochemie)|Rezeptor]] für [[CD70]] (synonym ''CD27L''). Es wird von [[T-Zellen]] gebildet und hemmt die [[SIVA1]]-abhängige [[Apoptose]]. CD27 ist eine [[Cysteinprotease]] und ein [[Immun-Checkpoint]]. Es ist [[glykosyliert]] und [[phosphoryliert]].

CD27 bindet an SIVA1,<ref name=pmid9177220>{{cite journal | author = Prasad KV, Ao Z, Yoon Y, Wu MX, Rizk M, Jacquot S, Schlossman SF | title = CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein | journal = [[Proceedings of the National Academy of Sciences]] | volume = 94 | issue = 12 | pages = 6346–51 | date = 1997-06 | pmid = 9177220 | pmc = 21052 | doi = 10.1073/pnas.94.12.6346 }}</ref> [[TRAF2]]<ref name=pmid9794406>{{cite journal | author = Yamamoto H, Kishimoto T, Minamoto S | title = NF-kappaB activation in CD27 signaling: involvement of TNF receptor-associated factors in its signaling and identification of functional region of CD27 | journal = Journal of Immunology | volume = 161 | issue = 9 | pages = 4753–9 | date = 1998-11 | pmid = 9794406 }}</ref><ref name=pmid9582383>{{cite journal | author = Akiba H, Nakano H, Nishinaka S, Shindo M, Kobata T, Atsuta M, Morimoto C, Ware CF, Malinin NL, Wallach D, Yagita H, Okumura K | title = CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase | journal = The Journal of Biological Chemistry | volume = 273 | issue = 21 | pages = 13353–8 | date = 1998-05 | pmid = 9582383 | doi = 10.1074/jbc.273.21.13353 }}</ref> und [[TRAF3]].<ref name=pmid9794406/><ref name=pmid9582383/>

Der anti-CD27-Antikörper [[Varlilumab]] bindet an CD27 und wird zur [[Krebsimmuntherapie]] eingesetzt.

== Weblinks ==
* {{MeshName|CD27+antigen}}

== Einzelnachweise ==
<references />

[[Kategorie:Protein]]
[[Kategorie:Codiert auf Chromosom 12 (Mensch)]]